---
title: Ataxia Evaluation
description: Clinical decision support for the evaluation and management of acute, subacute, and chronic ataxia in adults, including cerebellar and sensory ataxia.
version: "1.1"
setting: ED, HOSP, OPD, ICU
status: approved
tags:
  - movement-disorders
  - ataxia
  - cerebellar
  - neurodegenerative
  - autoimmune
---

# Ataxia Evaluation

**VERSION:** 1.1
**CREATED:** January 30, 2026
**REVISED:** January 31, 2026
**STATUS:** Approved

---

**DIAGNOSIS:** Ataxia Evaluation

**ICD-10:** R27.0 (Ataxia, unspecified), G11.9 (Hereditary ataxia, unspecified), G11.1 (Early-onset cerebellar ataxia), G11.2 (Late-onset cerebellar ataxia), G11.0 (Congenital nonprogressive ataxia), G11.3 (Cerebellar ataxia with defective DNA repair), G11.4 (Hereditary spastic paraplegia), G31.89 (Other specified degenerative diseases of nervous system — cerebellar degeneration NOS), G32.81 (Cerebellar ataxia in diseases classified elsewhere), G13.1 (Other systemic atrophy primarily affecting central nervous system in neoplastic disease — paraneoplastic cerebellar degeneration)

**CPT CODES:** 85025 (CBC with differential), 80053 (CMP), 82947 (Blood glucose), 84443 (TSH), 82607 (Vitamin B12), 82746 (Folate), 82608 (Vitamin E level), 83735 (Magnesium), 85652 (ESR), 80320 (Blood alcohol level), 86235 (Anti-GAD65 antibodies), 86258 (Anti-gliadin antibodies (IgA and IgG)), 86364 (Tissue transglutaminase IgA), 86255 (Paraneoplastic antibody panel), 83921 (Methylmalonic acid), 83090 (Homocysteine), 84425 (Thiamine (vitamin B1) level), 82525 (24-hour urine copper), 80061 (Lipid panel), 83036 (HbA1c), 86592 (RPR/VDRL), 87389 (HIV screening), 81401 (Genetic testing — SCA panel), 81284 (Genetic testing — Friedreich ataxia (FXN gene)), 81408 (Genetic testing — ataxia-telangiectasia (ATM gene)), 81406 (Genetic testing — episodic ataxia (CACNA1A, KCNA1)), 81415 (Whole exome sequencing), 82542 (Very long chain fatty acids (VLCFA)), 82105 (Alpha-fetoprotein (AFP)), 70450 (CT head without contrast), 70553 (MRI brain with and without contrast), 74177 (CT chest/abdomen/pelvis with contrast), 78816 (PET-CT), 95907-95913 (Nerve conduction study / Electromyography (NCS/EMG)), 95816 (Electroencephalogram (EEG)), 76390 (MR spectroscopy of cerebellum), 78830 (DAT scan (DaTscan, ioflupane SPECT)), 75557 (Cardiac MRI), 93306 (Echocardiogram (TTE)), 95923 (Autonomic function testing)

**SYNONYMS:** Ataxia, cerebellar ataxia, sensory ataxia, gait ataxia, limb ataxia, truncal ataxia, spinocerebellar ataxia, SCA, Friedreich ataxia, Friedreich's ataxia, hereditary ataxia, acquired ataxia, paraneoplastic cerebellar degeneration, autoimmune cerebellar ataxia, gluten ataxia, alcohol cerebellar degeneration, episodic ataxia, ataxia-telangiectasia, MSA-C, multiple system atrophy cerebellar type, sporadic adult-onset ataxia, SAOA, incoordination, unsteady gait, cerebellar syndrome, imbalance

**SCOPE:** Evaluation and management of ataxia in adults. Covers the differential diagnosis approach to cerebellar vs. sensory ataxia, acute/subacute etiologies (stroke, toxic, infectious, paraneoplastic, autoimmune), and chronic/progressive etiologies (hereditary, degenerative, immune-mediated). Includes diagnostic workup, etiology-directed treatment, symptomatic management, and rehabilitation. Excludes isolated vertigo (see Vertigo/Dizziness Evaluation), ataxia in children, and ataxia secondary to acute intoxication without persistent deficits.

---

**DEFINITIONS:**
- **Cerebellar ataxia:** Incoordination due to cerebellar dysfunction; characterized by dysmetria, intention tremor, dysdiadochokinesia, nystagmus, dysarthria (scanning speech), and wide-based gait
- **Sensory ataxia:** Incoordination due to impaired proprioception (dorsal columns, peripheral nerves); characterized by Romberg sign, pseudoathetosis, loss of vibration/position sense, worsened by eye closure
- **Acute ataxia:** Onset within hours to days (stroke, toxic, infectious)
- **Subacute ataxia:** Onset over weeks to months (paraneoplastic, autoimmune, nutritional)
- **Chronic ataxia:** Onset over months to years (hereditary, degenerative)
- **Episodic ataxia:** Recurrent discrete episodes of ataxia with return to baseline (genetic channelopathies)

---

**PRIORITY KEY:** STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting

===============================================================
SECTION A: ACTION ITEMS
===============================================================

## 1. LABORATORY WORKUP

### 1A. Essential/Core Labs

| Test | Rationale | Target Finding | ED | HOSP | OPD | ICU |
|------|-----------|----------------|:--:|:----:|:---:|:---:|
| CBC with differential (CPT 85025) | Infection screen (cerebellitis, abscess); anemia (B12 deficiency); malignancy (paraneoplastic) | Normal; leukocytosis suggests infection; macrocytic anemia suggests B12/folate deficiency | STAT | STAT | ROUTINE | STAT |
| CMP (CPT 80053) | Electrolyte derangements (hyponatremia, uremia); hepatic encephalopathy; renal dysfunction affecting drug clearance | Normal; hyponatremia <130 mEq/L can cause neurologic symptoms; elevated ammonia/LFTs suggest hepatic cause | STAT | STAT | ROUTINE | STAT |
| Blood glucose (CPT 82947) | Hypoglycemia can mimic acute cerebellar dysfunction; diabetes as comorbidity in neuropathic ataxia | 70-180 mg/dL | STAT | STAT | ROUTINE | STAT |
| TSH (CPT 84443) | Hypothyroidism can cause cerebellar ataxia (rare but treatable); thyroid dysfunction in autoimmune conditions | Normal (0.4-4.0 mIU/L); hypothyroidism → thyroid replacement | - | ROUTINE | ROUTINE | - |
| Vitamin B12 (CPT 82607) | B12 deficiency causes subacute combined degeneration with sensory ataxia; posterior column disease | >300 pg/mL; low or borderline → methylmalonic acid and homocysteine | URGENT | URGENT | ROUTINE | URGENT |
| Folate (CPT 82746) | Folate deficiency can contribute to neuropathy and myelopathy causing sensory ataxia | Normal (>5.9 ng/mL); low → supplement | - | ROUTINE | ROUTINE | - |
| Vitamin E level (CPT 82608) | Vitamin E deficiency causes spinocerebellar syndrome mimicking Friedreich ataxia; fat malabsorption states | Normal (5.5-17 mg/L); deficiency → supplement and evaluate malabsorption | - | ROUTINE | ROUTINE | - |
| Magnesium (CPT 83735) | Hypomagnesemia can contribute to ataxia and tremor; often low in alcoholism | Normal (1.7-2.2 mg/dL); low → replace | STAT | STAT | ROUTINE | STAT |
| ESR (CPT 85652) / CRP (CPT 86140) | Inflammatory markers for autoimmune, infectious, or paraneoplastic etiologies | Normal; elevated → further autoimmune/infectious workup | URGENT | URGENT | ROUTINE | URGENT |
| Drug levels (phenytoin, lithium, carbamazepine) (CPT 80185/80178/80156) | Drug toxicity is common reversible cause of cerebellar ataxia; phenytoin toxicity is classic cause | Phenytoin 10-20 mcg/mL; lithium 0.6-1.2 mEq/L; carbamazepine 4-12 mcg/mL; supratherapeutic levels → dose adjust or discontinue | STAT | STAT | ROUTINE | STAT |
| Blood alcohol level (CPT 80320) | Acute alcohol intoxication; chronic alcoholic cerebellar degeneration | Negative or low; elevated → address intoxication | STAT | STAT | - | STAT |
| Urinalysis with drug screen (CPT 81003/80307) | Toxic exposures; illicit substances causing ataxia | Negative; positive → identify offending agent | STAT | STAT | - | STAT |

### 1B. Extended Workup (Second-line)

| Test | Rationale | Target Finding | ED | HOSP | OPD | ICU |
|------|-----------|----------------|:--:|:----:|:---:|:---:|
| Anti-GAD65 antibodies (CPT 86235) | Autoimmune cerebellar ataxia; stiff-person spectrum; high titers (>2000 IU/mL) associated with cerebellar ataxia | Negative; positive at high titers → autoimmune cerebellar ataxia | - | URGENT | ROUTINE | - |
| Anti-gliadin antibodies (IgA and IgG) (CPT 86258) | Gluten ataxia is most common autoimmune cause of sporadic ataxia; may occur without GI symptoms | Negative; positive → trial gluten-free diet; tissue transglutaminase (tTG) for celiac confirmation | - | ROUTINE | ROUTINE | - |
| Tissue transglutaminase IgA (CPT 86364) | Celiac disease confirmation when anti-gliadin positive; gluten ataxia | Negative; positive → confirm with duodenal biopsy; strict gluten-free diet | - | ROUTINE | ROUTINE | - |
| Paraneoplastic antibody panel (CPT 86255) | Paraneoplastic cerebellar degeneration (PCD); anti-Yo (ovarian, breast), anti-Hu (small cell lung), anti-Tr/DNER (Hodgkin lymphoma), anti-mGluR1, anti-CV2/CRMP5 | Negative; positive → CT chest/abdomen/pelvis and PET-CT for occult malignancy | - | URGENT | ROUTINE | - |
| Methylmalonic acid (CPT 83921) | Confirms functional B12 deficiency when B12 borderline (200-400 pg/mL) | Normal (<0.4 mcmol/L); elevated → B12 deficiency confirmed | - | ROUTINE | ROUTINE | - |
| Homocysteine (CPT 83090) | Elevated in B12 and folate deficiency; vascular risk factor | Normal (<15 mcmol/L); elevated → supplement B12/folate | - | ROUTINE | ROUTINE | - |
| ANA (CPT 86235) | Systemic autoimmune conditions causing CNS involvement (SLE cerebritis, Sjogren syndrome) | Negative; positive → further autoimmune workup (dsDNA, SSA/SSB, complement) | - | ROUTINE | ROUTINE | - |
| Copper and ceruloplasmin (CPT 82390/82390) | Wilson disease (onset typically <50 years); copper deficiency from zinc excess or malabsorption can cause ataxia | Ceruloplasmin >20 mg/dL; low ceruloplasmin + low serum copper → Wilson disease; low copper → copper deficiency myelopathy | - | ROUTINE | ROUTINE | - |
| Thiamine (vitamin B1) level (CPT 84425) | Wernicke encephalopathy (ataxia, ophthalmoplegia, confusion); alcoholism, malnutrition | Normal (70-180 nmol/L); low → IV thiamine replacement urgently | STAT | STAT | ROUTINE | STAT |
| 24-hour urine copper (CPT 82525) | Wilson disease confirmation; elevated urinary copper excretion | <40 mcg/24h normal; >100 mcg/24h suggestive of Wilson disease | - | ROUTINE | ROUTINE | - |
| Lipid panel (CPT 80061) | Vascular risk factors if stroke-related cerebellar infarction | LDL <70 (high risk); assess global vascular risk | - | ROUTINE | ROUTINE | - |
| HbA1c (CPT 83036) | Diabetic neuropathy contributing to sensory ataxia; vascular risk | <7.0%; elevated → diabetes management | - | ROUTINE | ROUTINE | - |
| RPR/VDRL (CPT 86592) | Neurosyphilis (tabes dorsalis causing sensory ataxia); rare but treatable | Negative; positive → FTA-ABS confirmation and CSF analysis | - | ROUTINE | ROUTINE | - |
| HIV screening (CPT 87389) | HIV-associated cerebellar degeneration; opportunistic infections (PML, toxoplasmosis); medication-related | Negative; positive → CD4 count, viral load, CNS evaluation | - | ROUTINE | ROUTINE | - |

### 1C. Rare/Specialized (Refractory or Atypical)

| Test | Rationale | Target Finding | ED | HOSP | OPD | ICU |
|------|-----------|----------------|:--:|:----:|:---:|:---:|
| Genetic testing — SCA panel (CPT 81401) | Spinocerebellar ataxia types 1, 2, 3, 6, 7, 8, 10, 12, 17; repeat expansion testing; family history of progressive ataxia | Negative; positive → specific SCA subtype identified; genetic counseling | - | - | EXT | - |
| Genetic testing — Friedreich ataxia (FXN gene) (CPT 81284) | Friedreich ataxia (GAA repeat expansion); onset typically <25 years; cardiomyopathy, scoliosis, diabetes | Negative; positive (>66 GAA repeats on both alleles) → cardiologic evaluation, diabetes screening | - | - | EXT | - |
| Genetic testing — ataxia-telangiectasia (ATM gene) (CPT 81408) | Ataxia-telangiectasia; childhood onset but mild forms present in adults; telangiectasias, immunodeficiency, cancer predisposition | Negative; positive → cancer surveillance, immunology referral | - | - | EXT | - |
| Genetic testing — episodic ataxia (CACNA1A, KCNA1) (CPT 81406) | Episodic ataxia type 1 (KCNA1) and type 2 (CACNA1A); recurrent episodes; EA2 responsive to acetazolamide | Negative; positive → targeted therapy (acetazolamide for EA2) | - | - | EXT | - |
| Whole exome sequencing (CPT 81415) | Undiagnosed hereditary ataxia after targeted panels negative; novel or rare genetic causes | Variant of uncertain significance or pathogenic variant identified; many ataxias have no known genetic cause | - | - | EXT | - |
| Anti-mGluR1 antibodies | Autoimmune cerebellar ataxia; Hodgkin lymphoma association | Negative; positive → malignancy search and immunotherapy | - | - | EXT | - |
| Anti-DPPX antibodies | Autoimmune encephalitis with ataxia, hyperexcitability, diarrhea | Negative; positive → immunotherapy | - | - | EXT | - |
| Anti-CASPR2 antibodies (CPT 86255) | Autoimmune cerebellar ataxia; neuromyotonia; Morvan syndrome | Negative; positive → immunotherapy, thymoma search | - | - | EXT | - |
| Very long chain fatty acids (VLCFA) (CPT 82542) | Adrenomyeloneuropathy (X-linked); peroxisomal disorders causing ataxia and myelopathy | Normal; elevated → adrenoleukodystrophy/adrenomyeloneuropathy | - | - | EXT | - |
| Alpha-fetoprotein (AFP) (CPT 82105) | Elevated in ataxia-telangiectasia; screening marker | Normal; elevated → ataxia-telangiectasia evaluation | - | - | EXT | - |
| CoQ10 level (CPT 82542) | Coenzyme Q10 deficiency causes treatable cerebellar ataxia | Normal; low → CoQ10 supplementation (responds well) | - | - | EXT | - |
| Phytanic acid (CPT 82542) | Refsum disease (phytanic acid oxidase deficiency); ataxia, retinitis pigmentosa, neuropathy | Normal; elevated → dietary modification (phytanic acid restriction) | - | - | EXT | - |

---

## 2. DIAGNOSTIC IMAGING & STUDIES

### 2A. Essential/First-line

| Study | Timing | Target Finding | Contraindications | ED | HOSP | OPD | ICU |
|-------|--------|----------------|-------------------|:--:|:----:|:---:|:---:|
| CT head without contrast (CPT 70450) | STAT in acute ataxia for hemorrhage or mass effect; does NOT adequately visualize posterior fossa | Cerebellar hemorrhage; posterior fossa mass; hydrocephalus; large cerebellar infarction with edema; **NEGATIVE CT does NOT exclude posterior fossa stroke** | None for non-contrast | STAT | STAT | - | STAT |
| MRI brain with and without contrast (CPT 70553) | Gold standard for cerebellar evaluation; assess atrophy pattern, lesions, enhancement; DWI for acute stroke | Cerebellar atrophy (global vs. vermian vs. hemispheric); acute infarction on DWI; demyelinating lesions (MS); tumor; abscess; enhancement (inflammation, tumor) | MRI-incompatible implants; severe claustrophobia; GFR <30 for gadolinium | URGENT | URGENT | ROUTINE | URGENT |
| MRA head and neck (CPT 70544/70547) or CTA head and neck (CPT 70496/70498) | If vascular etiology suspected (vertebrobasilar stroke, dissection) | Vertebral artery dissection or stenosis; basilar artery stenosis or occlusion; posterior circulation aneurysm | MRA: MRI-incompatible implants, severe claustrophobia, GFR <30 for gadolinium; CTA: contrast allergy, renal impairment | URGENT | URGENT | ROUTINE | URGENT |

### 2B. Extended

| Study | Timing | Target Finding | Contraindications | ED | HOSP | OPD | ICU |
|-------|--------|----------------|-------------------|:--:|:----:|:---:|:---:|
| MRI cervical and thoracic spine (CPT 72141/72146) | If sensory ataxia suspected; dorsal column disease; myelopathy; B12 deficiency; copper deficiency | Dorsal column hyperintensity (subacute combined degeneration); compressive myelopathy; demyelinating lesions; syrinx | MRI-incompatible implants | - | URGENT | ROUTINE | - |
| CT chest/abdomen/pelvis with contrast (CPT 74177) | Paraneoplastic cerebellar degeneration — malignancy search when paraneoplastic antibodies positive | Occult malignancy (lung, ovarian, breast, lymphoma); thymoma | Contrast allergy; renal impairment | - | URGENT | ROUTINE | - |
| PET-CT (CPT 78816) | Occult malignancy search when paraneoplastic antibodies positive and CT negative | Hypermetabolic lesion suggesting occult neoplasm; small cell lung cancer, ovarian cancer, Hodgkin lymphoma | Pregnancy; significant hyperglycemia | - | URGENT | ROUTINE | - |
| Nerve conduction study / Electromyography (NCS/EMG) (CPT 95907-95913) | Sensory ataxia evaluation; peripheral neuropathy; Friedreich ataxia (sensory neuropathy); CIDP; paraneoplastic neuropathy | Sensory neuropathy (reduced SNAP amplitudes); sensory neuronopathy (non-length-dependent); demyelinating neuropathy (CIDP) | Anticoagulation (relative for EMG) | - | ROUTINE | ROUTINE | - |
| Electroencephalogram (EEG) (CPT 95816) | If seizures suspected; progressive myoclonus ataxia syndromes; prion disease (periodic sharp waves) | Normal background; epileptiform discharges; periodic sharp wave complexes (CJD); myoclonic correlates | None | - | ROUTINE | ROUTINE | - |

### 2C. Rare/Specialized

| Study | Timing | Target Finding | Contraindications | ED | HOSP | OPD | ICU |
|-------|--------|----------------|-------------------|:--:|:----:|:---:|:---:|
| MR spectroscopy of cerebellum (CPT 76390) | Evaluate cerebellar metabolites in neurodegenerative ataxia; NAA reduction in neuronal loss | Reduced NAA/Cr ratio (neuronal loss); elevated choline (inflammation or tumor); lactate peak (mitochondrial disease) | MRI-incompatible implants; severe claustrophobia; GFR <30 for gadolinium | - | - | EXT | - |
| DAT scan (DaTscan, ioflupane SPECT) (CPT 78830) | Differentiate MSA-C from cerebellar ataxia without parkinsonism; presynaptic dopaminergic deficit | Normal uptake (pure cerebellar) vs. reduced uptake (MSA-C, Parkinson-plus) | None significant | - | - | EXT | - |
| Cardiac MRI (CPT 75557) | Friedreich ataxia — hypertrophic cardiomyopathy screening; cardiac iron deposition | Normal; hypertrophic cardiomyopathy; myocardial fibrosis | MRI-incompatible implants; claustrophobia | - | - | EXT | - |
| Echocardiogram (TTE) (CPT 93306) | Friedreich ataxia — cardiomyopathy screening; MSA — autonomic cardiac involvement | Normal; hypertrophic or dilated cardiomyopathy (Friedreich); LV dysfunction | None | - | ROUTINE | ROUTINE | - |
| Autonomic function testing (CPT 95923) | MSA-C evaluation; autonomic failure (orthostatic hypotension, urinary dysfunction, anhidrosis) | Normal; abnormal (cardiovagal, adrenergic, or sudomotor dysfunction) → supports MSA-C diagnosis | None significant | - | - | EXT | - |

### LUMBAR PUNCTURE

**Indication:** Subacute ataxia with suspected infectious, inflammatory, autoimmune, or neoplastic etiology; acute ataxia if meningoencephalitis suspected
**Timing:** URGENT if acute/subacute presentation; ROUTINE for chronic ataxia evaluation
**Volume Required:** 10-15 mL standard diagnostic

| Study | Rationale | Target Finding | ED | HOSP | OPD | ICU |
|-------|-----------|----------------|:--:|:----:|:---:|:---:|
| Opening pressure | Elevated ICP (mass lesion, hydrocephalus, meningitis) | 10-20 cm H2O; elevated → obtain imaging before LP; initiate ICP management | URGENT | URGENT | ROUTINE | - |
| Cell count (tubes 1 and 4) | Infection, inflammation, malignancy | WBC <5, RBC 0; pleocytosis → infection or inflammation; lymphocytic → viral, autoimmune, or paraneoplastic | URGENT | URGENT | ROUTINE | - |
| Protein | Infection, inflammation, Guillain-Barre variants | 15-45 mg/dL; elevated → infection, inflammation, malignancy; markedly elevated → GBS variant (Miller Fisher) | URGENT | URGENT | ROUTINE | - |
| Glucose with serum glucose | Infection (bacterial, TB, fungal) | CSF/serum ratio >0.6; low ratio → bacterial, TB, fungal, or carcinomatous meningitis | URGENT | URGENT | ROUTINE | - |
| Gram stain and culture | Bacterial meningitis; brain abscess rupture | No organisms; positive → targeted antibiotics | URGENT | URGENT | - | - |
| Oligoclonal bands and IgG index | Multiple sclerosis; other inflammatory CNS disease | Absent; present → MS or other inflammatory condition | - | ROUTINE | ROUTINE | - |
| Cytology | Leptomeningeal carcinomatosis; CNS lymphoma | Negative; positive → oncology referral | - | ROUTINE | ROUTINE | - |
| Anti-GAD65 in CSF | Intrathecal anti-GAD production in autoimmune cerebellar ataxia | Negative; positive (especially with high index vs. serum) → autoimmune cerebellar ataxia | - | ROUTINE | ROUTINE | - |
| Paraneoplastic antibodies in CSF | More sensitive than serum for some paraneoplastic antibodies | Negative; positive → malignancy search | - | ROUTINE | ROUTINE | - |
| 14-3-3 protein and RT-QuIC | Prion disease (Creutzfeldt-Jakob disease) if rapidly progressive ataxia with cognitive decline | Negative; positive → CJD highly likely | - | ROUTINE | EXT | - |

**Special Handling:** CSF for cytology must be processed within 1 hour; paraneoplastic and autoimmune panels require specific handling per reference laboratory
**Contraindications:** Posterior fossa mass with risk of herniation; severe coagulopathy (INR >1.5, platelets <50,000); skin infection at puncture site

---

## 3. TREATMENT

### 3A. Acute/Emergent Treatment

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| Thiamine (vitamin B1) | IV | Wernicke encephalopathy (ataxia + ophthalmoplegia + confusion); empiric in alcoholism or malnutrition with acute ataxia | 500 mg :: IV :: TID x 3 days :: 500 mg IV TID for 3 days, then 250 mg IV daily for 5 days; give BEFORE glucose; infuse over 30 min | Rare anaphylaxis (IV formulation) | Allergic reaction during infusion; clinical improvement (ophthalmoplegia resolves first, then confusion, then ataxia) | STAT | STAT | - | STAT |
| IV alteplase (tPA) | IV | Acute posterior circulation ischemic stroke causing cerebellar infarction within treatment window | 0.9 mg/kg :: IV :: once (max 90 mg) :: 0.9 mg/kg IV (max 90 mg); 10% bolus over 1 min, remainder over 60 min; within 4.5 hours of symptom onset | Active hemorrhage; recent surgery; INR >1.7; platelets <100,000; BP >185/110; see full stroke exclusion criteria | BP q15min x 2h, then q30min x 6h, then q1h x 16h; neuro checks q15min during infusion; NIHSS; signs of hemorrhage | STAT | STAT | - | STAT |
| Tenecteplase | IV | Alternative thrombolytic for acute posterior circulation stroke; single bolus dosing | 0.25 mg/kg :: IV :: once (max 25 mg) :: 0.25 mg/kg IV bolus (max 25 mg); single dose; emerging evidence for posterior circulation | Active hemorrhage; recent surgery; INR >1.7; platelets <100,000; BP >185/110; see full stroke exclusion criteria | BP q15min x 2h, then q30min x 6h, then q1h x 16h; neuro checks q15min during infusion; NIHSS; signs of hemorrhage | STAT | STAT | - | STAT |
| Dexamethasone | IV | Vasogenic edema from cerebellar mass (tumor, abscess); NOT for cytotoxic edema (stroke) | 10 mg :: IV :: load, then 4 mg q6h :: 10 mg IV loading dose, then 4 mg IV q6h; for tumor/abscess-related edema only | Active GI bleeding; uncontrolled infection (relative); avoid in stroke | Blood glucose q6h; GI prophylaxis (PPI); mood changes; insomnia | STAT | STAT | - | STAT |
| Mannitol | IV | Elevated ICP from posterior fossa mass effect with impending herniation; cerebellar stroke with edema | 1 g/kg :: IV :: bolus, then 0.25-0.5 g/kg q6h PRN :: 1 g/kg IV bolus over 15-20 min; then 0.25-0.5 g/kg q6h PRN; target serum osmolality <320 | Severe dehydration; anuria; pulmonary edema | Serum osmolality q6h (hold if >320); BMP q6h; urine output; neuro exam | STAT | STAT | - | STAT |
| Hypertonic saline (23.4%) | IV | Acute ICP crisis from posterior fossa mass effect when rapid osmotic effect needed | 30 mL :: IV :: bolus over 10-15 min :: 30 mL of 23.4% NaCl IV over 10-15 min via central line; may repeat if needed | Severe hypernatremia (Na >160); CHF | Serum sodium q4-6h (target 145-155); central line required for 23.4%; serum osmolality | STAT | STAT | - | STAT |
| Phenytoin dose adjustment or discontinuation | IV/PO | Phenytoin toxicity causing cerebellar ataxia (most common drug-induced cause); supratherapeutic level | N/A :: IV/PO :: per level :: Hold phenytoin; recheck level in 24-48h; resume at lower dose or switch to alternative AED; chronic toxicity may cause permanent cerebellar damage | Do not abruptly discontinue if on for seizures — taper and bridge | Repeat phenytoin level q12-24h until therapeutic; monitor for seizure breakthrough if reducing dose | STAT | STAT | ROUTINE | STAT |
| Lithium dose adjustment or discontinuation | PO | Lithium toxicity causing cerebellar ataxia; supratherapeutic level | N/A :: PO :: per level :: Hold lithium; aggressive IV hydration; recheck level q6-12h; hemodialysis if level >4.0 or severe symptoms; resume at lower dose when level therapeutic | Psychiatry consult before discontinuation; monitor for rebound mania | Lithium level q6-12h; BMP q6-12h; renal function; neurologic exam; hemodialysis if level >4.0 | STAT | STAT | - | STAT |

### 3B. Symptomatic Treatments

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| Acetazolamide | PO | Episodic ataxia type 2 (EA2, CACNA1A mutation); first-line preventive therapy; reduces frequency and severity of episodes | 250 mg :: PO :: BID :: Start 250 mg BID; titrate to 250-500 mg BID-TID based on response; max 1000 mg/day | Sulfonamide allergy; severe hepatic or renal impairment; metabolic acidosis; hypokalemia | BMP q3 months (metabolic acidosis, hypokalemia); renal function; paresthesias (common, benign); kidney stones (hydration) | - | ROUTINE | ROUTINE | - |
| 4-Aminopyridine (dalfampridine) | PO | Episodic ataxia type 2; downbeat nystagmus; cerebellar gait ataxia; improves Purkinje cell function | 5 mg :: PO :: BID :: Start 5 mg BID; may increase to 10 mg BID; 12 hours apart; max 20 mg/day | Seizure history (lowers seizure threshold); moderate-severe renal impairment (CrCl <50); concurrent use of other forms of 4-AP | Seizure risk; renal function at baseline and periodically; GI side effects | - | ROUTINE | ROUTINE | - |
| Riluzole | PO | Some spinocerebellar ataxias (SCA); neuroprotective; modest evidence for ataxia improvement in selected patients | 50 mg :: PO :: BID :: 50 mg PO BID; take on empty stomach (1 hour before or 2 hours after meals) | Hepatic impairment (ALT >5x ULN); pregnancy | LFTs monthly x 3 months, then q3 months for first year, then periodically; neutrophil count; nausea, asthenia | - | - | ROUTINE | - |
| Amantadine | PO | Cerebellar ataxia (various etiologies); modest evidence for gait improvement; anti-glutamatergic properties | 100 mg :: PO :: daily :: Start 100 mg daily; increase to 100 mg BID-TID over 1-2 weeks; max 300 mg/day; avoid afternoon dosing (insomnia) | Severe renal impairment (dose adjust if CrCl <50); seizure history; livedo reticularis; angle-closure glaucoma | Renal function; hallucinations (especially elderly); insomnia; livedo reticularis; ankle edema | - | ROUTINE | ROUTINE | - |
| Buspirone | PO | Cerebellar ataxia (various etiologies); serotonergic mechanism may improve cerebellar function; modest evidence | 5 mg :: PO :: TID :: Start 5 mg TID; increase by 5 mg/dose q3-5 days; target 30-60 mg/day divided TID; max 60 mg/day | Concurrent MAOIs; severe hepatic or renal impairment | Dizziness; headache; nausea (usually transient); no dependence risk unlike benzodiazepines | - | ROUTINE | ROUTINE | - |
| Gabapentin | PO | Neuropathic pain in sensory ataxia; proprioceptive neuropathy symptoms; cerebellar tremor | 300 mg :: PO :: qHS :: Start 300 mg qHS; titrate by 300 mg q3d; target 900-1800 mg/day divided TID; max 3600 mg/day; adjust for renal function | Severe renal impairment (dose adjust); respiratory depression with opioids or CNS depressants | Sedation; dizziness; peripheral edema; renal function; suicidality (rare); respiratory depression if combined with CNS depressants | - | ROUTINE | ROUTINE | - |
| Pregabalin | PO | Neuropathic pain in sensory ataxia; may help cerebellar tremor | 75 mg :: PO :: BID :: Start 75 mg BID; increase to 150 mg BID after 1 week; max 600 mg/day; adjust for renal function | Severe renal impairment (dose adjust); angioedema history | Sedation; dizziness; weight gain; peripheral edema; renal function | - | ROUTINE | ROUTINE | - |
| Clonazepam | PO | Cerebellar tremor; myoclonus in progressive myoclonic ataxia; action tremor refractory to other treatments | 0.25 mg :: PO :: BID :: Start 0.25 mg BID; increase by 0.25 mg q3-5 days; target 0.5-2 mg/day; max 4 mg/day; use lowest effective dose | Respiratory insufficiency; severe hepatic impairment; acute narrow-angle glaucoma; avoid abrupt discontinuation | Sedation; respiratory depression; dependence (limit duration); fall risk; cognitive impairment; paradoxical agitation (elderly) | - | ROUTINE | ROUTINE | - |
| Propranolol | PO | Cerebellar action tremor (kinetic/intention tremor component); reduces tremor amplitude | 20 mg :: PO :: BID :: Start 20 mg BID; titrate by 20 mg/dose q1 week; max 320 mg/day; use LA formulation for once-daily dosing | Asthma/severe COPD (non-selective beta-blocker); bradycardia (HR <50); AV block (2nd/3rd degree); decompensated heart failure; severe peripheral vascular disease | Heart rate; blood pressure; blood glucose (masks hypoglycemia in diabetics); fatigue; depression | - | ROUTINE | ROUTINE | - |
| Ondansetron | IV/PO | Nausea and vomiting associated with acute cerebellar dysfunction and vertigo | 4 mg :: IV/PO :: q8h PRN :: 4-8 mg IV/PO q8h PRN nausea; max 24 mg/day | QT prolongation; severe hepatic impairment (max 8 mg/day) | QTc if risk factors; constipation; headache | STAT | STAT | ROUTINE | STAT |
| Meclizine | PO | Vestibular symptoms (vertigo, nausea) associated with cerebellar ataxia; short-term use only | 25 mg :: PO :: q6-8h PRN :: 25 mg PO q6-8h PRN; short-term use only (48-72h); do NOT use chronically — delays vestibular compensation | Elderly (anticholinergic effects); urinary retention; glaucoma | Sedation; anticholinergic effects; discontinue within 72 hours; does not treat underlying cause | STAT | STAT | - | - |
| Modafinil | PO | Fatigue associated with chronic cerebellar disease; daytime somnolence from medications or disease | 100 mg :: PO :: daily :: Start 100 mg each morning; may increase to 200 mg daily; take before noon to avoid insomnia | Severe hepatic impairment; history of left ventricular hypertrophy; arrhythmia | Blood pressure; heart rate; insomnia; headache; may reduce efficacy of hormonal contraceptives | - | - | ROUTINE | - |
| Sertraline | PO | Depression and anxiety commonly comorbid with chronic ataxia; does not worsen ataxia | 25 mg :: PO :: daily :: Start 25 mg daily; increase by 25 mg q1-2 weeks; target 50-150 mg daily; max 200 mg/day | Concurrent MAOIs (14-day washout); concurrent pimozide | Suicidality (especially first 4 weeks); serotonin syndrome; GI upset; sexual dysfunction; hyponatremia (elderly) | - | ROUTINE | ROUTINE | - |

### 3C. Second-line/Refractory (Etiology-Specific Treatments)

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| IV methylprednisolone | IV | Autoimmune cerebellar ataxia (anti-GAD, paraneoplastic); MS cerebellar relapse; acute inflammatory cerebellitis | 1000 mg :: IV :: daily x 3-5 days :: 1000 mg IV daily for 3-5 days; infuse over 1 hour; may follow with oral prednisone taper | Active infection; uncontrolled diabetes; GI bleeding; psychosis | Blood glucose q6h; blood pressure; mood/sleep; GI prophylaxis (PPI); potassium | - | STAT | - | - |
| IVIG (intravenous immunoglobulin) | IV | Autoimmune cerebellar ataxia (anti-GAD); paraneoplastic cerebellar degeneration; Miller Fisher syndrome (GBS variant with ataxia); post-infectious cerebellitis | 0.4 g/kg :: IV :: daily x 5 days :: 0.4 g/kg/day IV for 5 days (total 2 g/kg); infuse slowly — start 0.5 mL/kg/h, increase to max 4 mL/kg/h; premedicate with acetaminophen and diphenhydramine | IgA deficiency (anaphylaxis risk — check IgA level); severe renal impairment; hypercoagulable state | Renal function (BMP before and after); headache (aseptic meningitis); thrombotic events; infusion reactions; vital signs during infusion | - | URGENT | - | - |
| Plasma exchange (PLEX) | IV | Autoimmune cerebellar ataxia refractory to steroids/IVIG; Miller Fisher syndrome; paraneoplastic cerebellar degeneration (limited benefit once neuronal loss established) | 1-1.5 plasma volumes :: IV :: q other day x 5-7 exchanges :: 5-7 exchanges over 10-14 days; 1-1.5 plasma volumes per exchange; albumin replacement | Hemodynamic instability; active infection; severe coagulopathy | Electrolytes (calcium, magnesium) q exchange; fibrinogen; blood pressure; line complications; infection | - | URGENT | - | - |
| Rituximab | IV | Refractory autoimmune cerebellar ataxia (anti-GAD, other antibody-mediated); gluten ataxia not responding to diet; MS cerebellar involvement | 1000 mg :: IV :: day 0 and day 14 :: 1000 mg IV on day 0 and day 14; repeat q6 months based on response or CD19/CD20 counts; premedicate with methylprednisolone, acetaminophen, diphenhydramine | Active hepatitis B (check HBsAg, anti-HBc before); active severe infection; severe heart failure | CBC with differential q3 months; immunoglobulin levels q6 months; hepatitis B reactivation screening; PML risk (rare); infusion reactions | - | ROUTINE | ROUTINE | - |
| Mycophenolate mofetil | PO | Steroid-sparing agent for chronic autoimmune cerebellar ataxia; maintenance immunosuppression | 500 mg :: PO :: BID :: Start 500 mg BID; increase to 1000 mg BID after 2 weeks; max 3000 mg/day (rarely needed) | Pregnancy (Category D — teratogenic); active infection; hypersensitivity | CBC q2 weeks x 3 months, then monthly; LFTs monthly; renal function; GI symptoms (diarrhea, nausea); infections; live vaccines contraindicated | - | ROUTINE | ROUTINE | - |
| Azathioprine | PO | Alternative steroid-sparing agent for autoimmune cerebellar ataxia; TPMT testing required | 50 mg :: PO :: daily :: Check TPMT before starting; start 50 mg daily; increase by 25 mg q2 weeks to target 2-2.5 mg/kg/day based on TPMT activity | TPMT deficiency (severe myelosuppression); concurrent allopurinol (reduce dose by 75%); pregnancy | CBC weekly x 4 weeks, then q2 weeks x 3 months, then monthly; LFTs monthly; TPMT genotype/phenotype before starting; infections; lymphoma risk (long-term) | - | ROUTINE | ROUTINE | - |
| Gluten-free diet | Dietary | Gluten ataxia (positive anti-gliadin antibodies); strict adherence required for benefit; improvement may take 6-12 months | N/A :: Dietary :: continuous :: Complete elimination of wheat, barley, rye, and cross-contaminated oats; dietitian referral essential; compliance monitoring with repeat anti-gliadin antibodies | None | Anti-gliadin antibody levels q6 months (should decrease with compliance); clinical ataxia scores (SARA, ICARS); nutritional status; B12 and iron | - | ROUTINE | ROUTINE | - |
| Coenzyme Q10 (CoQ10) | PO | CoQ10 deficiency (primary cerebellar ataxia responsive to supplementation); may benefit some mitochondrial ataxias | 300 mg :: PO :: BID :: Start 300 mg BID; increase to 600 mg BID if tolerated and deficiency confirmed; take with fatty meal for absorption; may take months for improvement | None significant | Clinical ataxia scores; CoQ10 levels if available; GI tolerance; well-tolerated | - | ROUTINE | ROUTINE | - |
| Vitamin B12 supplementation | IM/PO | B12 deficiency causing sensory ataxia (subacute combined degeneration); posterior column disease | 1000 mcg :: IM :: daily x 7 days :: 1000 mcg IM daily x 7 days, then weekly x 4 weeks, then monthly indefinitely; or high-dose oral 1000-2000 mcg daily if absorption adequate | None | B12 level at 2 months; MMA for adequacy of replacement; neurologic exam; CBC (reticulocyte response); sensory exam improvement may take months | URGENT | URGENT | ROUTINE | - |
| Vitamin E supplementation | PO | Vitamin E deficiency ataxia (abetalipoproteinemia, fat malabsorption); treatable cause | 800 IU :: PO :: daily :: 800-1200 IU daily; higher doses may be needed in malabsorption syndromes; take with fatty meal | Caution with anticoagulants (may increase bleeding risk at high doses) | Vitamin E levels q3 months initially; PT/INR if on anticoagulants; clinical ataxia assessment | - | ROUTINE | ROUTINE | - |
| Copper supplementation | PO/IV | Copper deficiency myelopathy and ataxia (zinc excess, bariatric surgery, malabsorption) | 2 mg :: PO/IV :: daily :: Acute: 2 mg IV daily x 5 days; Maintenance: 2 mg PO daily; remove cause (e.g., stop excess zinc) | Wilson disease (must be excluded before copper supplementation) | Serum copper and ceruloplasmin q3 months; zinc levels; CBC (copper deficiency causes anemia, neutropenia); neurologic exam | - | URGENT | ROUTINE | - |
| Idebenone | PO | Friedreich ataxia — may reduce cardiac hypertrophy; limited evidence for neurological benefit; investigational | 5 mg/kg :: PO :: TID :: 5 mg/kg TID (typically 150-300 mg TID); take with food; not FDA-approved but used off-label | None significant | Cardiac function (echocardiogram); LFTs; clinical ataxia scores; well-tolerated | - | - | EXT | - |
| Omaveloxolone (Skyclarys) | PO | Friedreich ataxia — FDA-approved Nrf2 activator; first approved therapy for Friedreich ataxia (2023) | 150 mg :: PO :: daily :: 150 mg PO once daily on empty stomach (1 hour before first meal); swallow capsule whole | Moderate-to-severe hepatic impairment; avoid strong CYP3A4 inhibitors; concurrent hepatotoxic drugs | LFTs at baseline, monthly x 3 months, then q3 months; BNP (cardiac); weight; clinical ataxia scores (mFARS) | - | - | ROUTINE | - |

### 3D. Disease-Modifying or Chronic Therapies

| Treatment | Route | Indication | Dosing | Pre-Treatment Requirements | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|---------------------------|-------------------|------------|:--:|:----:|:---:|:---:|
| Rituximab (maintenance) | IV | Long-term immunosuppression for autoimmune cerebellar ataxia (anti-GAD, CASPR2, other autoantibodies) | 1000 mg :: IV :: q6 months :: 1000 mg IV q6 months; adjust interval based on CD19/CD20 B cell counts and clinical response | HBsAg, anti-HBc, anti-HBs; quantitative immunoglobulins; CBC; LFTs; pregnancy test; vaccination update (live vaccines >4 weeks before) | Active hepatitis B; active severe infection; pregnancy; severe immunodeficiency | CD19/CD20 counts before each infusion; immunoglobulin levels q6 months; CBC q3 months; infections; PML screening (JCV risk very low with rituximab) | - | - | ROUTINE | - |
| Mycophenolate mofetil (maintenance) | PO | Steroid-sparing maintenance for chronic autoimmune cerebellar ataxia | 1000 mg :: PO :: BID :: 1000 mg BID; dose adjust based on CBC and GI tolerance | CBC; LFTs; renal function; pregnancy test (teratogenic); TPMT not required for mycophenolate | Pregnancy (Category D); active infection; live vaccines | CBC monthly; LFTs q3 months; renal function q3 months; GI tolerance; infections; malignancy surveillance (skin exam annually) | - | - | ROUTINE | - |
| Azathioprine (maintenance) | PO | Alternative steroid-sparing maintenance for autoimmune cerebellar ataxia | 2-2.5 mg/kg :: PO :: daily :: Target 2-2.5 mg/kg/day divided daily or BID; dose based on TPMT activity | TPMT genotype/phenotype; CBC; LFTs; renal function | TPMT deficiency; concurrent allopurinol (dose reduce 75%); pregnancy | CBC q2 weeks x 3 months, then monthly; LFTs monthly; infections; lymphoma risk (long-term); annual skin exam | - | - | ROUTINE | - |

---

## 4. OTHER RECOMMENDATIONS

### 4A. Referrals & Consults

| Recommendation | ED | HOSP | OPD | ICU |
|----------------|:--:|:----:|:---:|:---:|
| Neurology consultation for ataxia evaluation, localization (cerebellar vs. sensory), and diagnostic workup guidance | URGENT | URGENT | ROUTINE | URGENT |
| Movement disorders specialist referral for chronic or progressive ataxia requiring specialized evaluation and genetic testing interpretation | - | ROUTINE | ROUTINE | - |
| Stroke neurology consultation if acute cerebellar stroke suspected based on sudden onset, vascular risk factors, or central exam findings | STAT | STAT | - | STAT |
| Physical therapy for gait training, balance exercises, fall prevention, and adaptive strategies for progressive ataxia | - | ROUTINE | ROUTINE | - |
| Occupational therapy for fine motor training, adaptive equipment (weighted utensils, writing aids), and ADL modifications | - | ROUTINE | ROUTINE | - |
| Speech therapy for cerebellar dysarthria (scanning speech) evaluation and treatment; swallow evaluation if dysphagia present | - | ROUTINE | ROUTINE | - |
| Genetic counseling referral when hereditary ataxia (SCA, Friedreich, EA) is confirmed or suspected based on family history or genetic testing results | - | - | ROUTINE | - |
| Cardiology referral for Friedreich ataxia (cardiomyopathy screening) or MSA-C (autonomic cardiovascular dysfunction) | - | ROUTINE | ROUTINE | - |
| Neurosurgery consultation for posterior fossa mass lesion, large cerebellar stroke with mass effect, or obstructive hydrocephalus requiring intervention | STAT | STAT | - | STAT |
| Oncology referral for paraneoplastic cerebellar degeneration with identified or suspected malignancy | - | URGENT | URGENT | - |
| Psychiatry referral for depression or anxiety management in chronic progressive ataxia affecting quality of life | - | ROUTINE | ROUTINE | - |
| Dietitian referral for gluten-free diet implementation in gluten ataxia; nutritional assessment in malabsorption-related ataxia | - | ROUTINE | ROUTINE | - |
| Social work for disability resources, adaptive equipment funding, home safety assessment, and caregiver support in progressive ataxia | - | ROUTINE | ROUTINE | - |
| Palliative care referral for advanced degenerative ataxia (MSA-C, advanced SCA) for symptom management and goals of care discussion | - | ROUTINE | ROUTINE | - |

### 4B. Patient Instructions

| Recommendation | ED | HOSP | OPD | ICU |
|----------------|:--:|:----:|:---:|:---:|
| Return immediately for sudden worsening of ataxia, new headache, vomiting, or change in consciousness (may indicate stroke or mass lesion requiring emergency treatment) | STAT | STAT | ROUTINE | - |
| Return immediately for new double vision, slurred speech, weakness, or numbness (may indicate brainstem or cerebellar stroke) | STAT | STAT | ROUTINE | - |
| Do not drive until cleared by neurology due to impaired coordination and fall risk affecting vehicle control | ROUTINE | ROUTINE | ROUTINE | - |
| Use assistive devices (walker, cane) as recommended by physical therapy to prevent falls and injury | - | ROUTINE | ROUTINE | - |
| Remove tripping hazards at home (rugs, clutter, poor lighting) and install grab bars in bathroom to reduce fall risk | - | ROUTINE | ROUTINE | - |
| Do not stop or adjust seizure medications (phenytoin, carbamazepine) without physician guidance as this may cause breakthrough seizures | ROUTINE | ROUTINE | ROUTINE | - |
| Avoid alcohol as it worsens cerebellar function and may cause permanent cerebellar damage with chronic use | ROUTINE | ROUTINE | ROUTINE | - |
| For gluten ataxia: strictly avoid all wheat, barley, rye, and cross-contaminated products; improvement may take 6-12 months of strict adherence | - | ROUTINE | ROUTINE | - |
| Keep a symptom diary tracking episode frequency, duration, and triggers for episodic ataxia to guide treatment optimization | - | - | ROUTINE | - |
| Genetic testing results may have implications for family members; discuss with genetic counselor before sharing results | - | - | ROUTINE | - |

### 4C. Lifestyle & Prevention

| Recommendation | ED | HOSP | OPD | ICU |
|----------------|:--:|:----:|:---:|:---:|
| Alcohol cessation to prevent further cerebellar damage and reduce ongoing cerebellar toxicity (alcohol-related cerebellar degeneration primarily affects anterior vermis) | ROUTINE | ROUTINE | ROUTINE | - |
| Smoking cessation to reduce vascular risk factors for posterior circulation stroke and overall health improvement | - | ROUTINE | ROUTINE | - |
| Regular exercise program adapted to balance limitations (swimming, stationary bike, seated exercises) to maintain strength and cardiovascular health | - | ROUTINE | ROUTINE | - |
| Fall prevention strategies: adequate lighting, non-skid footwear, remove loose rugs, install handrails on both sides of stairs | - | ROUTINE | ROUTINE | - |
| Strict glycemic control (HbA1c <7%) if diabetic neuropathy contributing to sensory ataxia component | - | ROUTINE | ROUTINE | - |
| Mediterranean diet for vascular risk reduction in stroke-related ataxia; adequate nutrition in malabsorption-related ataxia | - | ROUTINE | ROUTINE | - |
| Vitamin B12 and folate-rich diet (meat, fish, dairy, leafy greens) to support nerve health and prevent deficiency-related ataxia | - | ROUTINE | ROUTINE | - |
| Weight management to reduce joint stress and improve mobility in patients with gait ataxia | - | - | ROUTINE | - |
| Stress management and adequate sleep (7-9 hours) as stress and fatigue may worsen ataxia symptoms and trigger episodic ataxia attacks | - | - | ROUTINE | - |
| Medic alert bracelet recommended for patients with episodic ataxia (may appear intoxicated during episodes) or Friedreich ataxia (cardiac risk) | - | - | ROUTINE | - |

---

===============================================================
SECTION B: SUPPORTING INFORMATION
===============================================================

## 5. DIFFERENTIAL DIAGNOSIS

### Ataxia Classification by Tempo

| Tempo | Etiologies | Key Distinguishing Features | Tests to Differentiate |
|-------|-----------|----------------------------|------------------------|
| **Acute (hours-days)** | Posterior fossa stroke (cerebellar infarct/hemorrhage), drug toxicity (phenytoin, lithium, alcohol), Wernicke encephalopathy, post-infectious cerebellitis, acute MS relapse, basilar migraine | Sudden onset; vascular risk factors (stroke); medication history (toxic); triad of ataxia/ophthalmoplegia/confusion (Wernicke); recent viral illness (post-infectious); prior MS or demyelinating events | CT head (hemorrhage); MRI DWI (stroke); drug levels; thiamine level; MRI with contrast (MS) |
| **Subacute (weeks-months)** | Paraneoplastic cerebellar degeneration, autoimmune (anti-GAD), gluten ataxia, vitamin deficiency (B12, E, thiamine), prion disease (CJD), CNS lymphoma, brain abscess | Progressive over weeks; weight loss/smoking (paraneoplastic); GI symptoms (gluten/celiac); dietary history (B12/E); rapid cognitive decline (CJD); fever/immunosuppression (abscess) | Paraneoplastic panel; anti-GAD; anti-gliadin; B12/E/thiamine; MRI; CSF (14-3-3, RT-QuIC for CJD) |
| **Chronic (months-years)** | Hereditary (SCA types, Friedreich, EA, AT), degenerative (MSA-C), alcoholic cerebellar degeneration, chronic drug exposure, idiopathic late-onset cerebellar ataxia | Family history (hereditary); progressive over years; autonomic failure (MSA-C); heavy alcohol use history; chronic medication exposure; anterior vermis atrophy on MRI (alcohol) | Genetic testing (SCA panel, Friedreich); MRI (atrophy pattern); autonomic testing (MSA); alcohol history |
| **Episodic (discrete attacks)** | Episodic ataxia type 1 (EA1), episodic ataxia type 2 (EA2), vestibular migraine, TIA (vertebrobasilar), metabolic decompensation | Attacks lasting minutes (EA1) or hours (EA2); myokymia between attacks (EA1); nystagmus between attacks (EA2); migraine features; vascular risk factors (TIA) | Genetic testing (KCNA1 for EA1, CACNA1A for EA2); MRI/MRA; headache history |

### Cerebellar vs. Sensory Ataxia

| Feature | Cerebellar Ataxia | Sensory Ataxia |
|---------|-------------------|----------------|
| **Romberg sign** | Negative or mildly positive (unsteady with eyes open AND closed) | Strongly positive (markedly worse with eyes closed) |
| **Proprioception** | Normal | Impaired (loss of vibration and position sense) |
| **Deep tendon reflexes** | Variable (may be normal or decreased) | Decreased or absent |
| **Dysmetria** | Present (finger-to-nose, heel-to-shin) | Absent or mild |
| **Nystagmus** | Present (gaze-evoked, downbeat, or positional) | Absent |
| **Dysarthria** | Scanning/explosive speech | Normal speech |
| **Gait** | Wide-based, irregular, cannot tandem walk | Wide-based, stamping gait, worse in dark/eyes closed |
| **Pseudoathetosis** | Absent | Present (involuntary writhing of outstretched fingers) |
| **MRI finding** | Cerebellar atrophy or lesion | Normal cerebellum; may show dorsal column signal change on spine MRI |
| **Common causes** | Stroke, alcohol, SCA, MSA-C, paraneoplastic, autoimmune | B12 deficiency, sensory neuropathy, dorsal column lesion, tabes dorsalis, Friedreich ataxia |

### Key Cerebellar Atrophy Patterns on MRI

| Pattern | Etiology |
|---------|----------|
| **Anterior vermis atrophy** | Alcohol-related cerebellar degeneration (classic pattern) |
| **Global cerebellar atrophy** | SCA types, MSA-C, paraneoplastic |
| **Hemispheric atrophy (unilateral)** | Prior stroke; focal lesion; post-radiation |
| **Pontocerebellar atrophy** | MSA-C (hot cross bun sign in pons on MRI); SCA1, SCA2, SCA7 |
| **No atrophy (early stage)** | Early paraneoplastic; acute causes; episodic ataxia |

### Common Paraneoplastic Antibodies in Cerebellar Degeneration

| Antibody | Associated Malignancy | Notes |
|----------|----------------------|-------|
| Anti-Yo (PCA-1) | Ovarian cancer, breast cancer | Most common paraneoplastic cerebellar antibody; poor neurological recovery |
| Anti-Hu (ANNA-1) | Small cell lung cancer | Often with sensory neuropathy (sensory ataxia + cerebellar) |
| Anti-Tr (DNER) | Hodgkin lymphoma | Good neurological recovery if lymphoma treated early |
| Anti-mGluR1 | Hodgkin lymphoma | Rare; good response to tumor treatment |
| Anti-CV2/CRMP5 | Small cell lung cancer, thymoma | Mixed neuropathy + cerebellar syndrome |
| Anti-VGCC (P/Q type) | Small cell lung cancer | Often with Lambert-Eaton syndrome |
| Anti-amphiphysin | Breast cancer, small cell lung cancer | Often with stiff-person spectrum |

---

## 6. MONITORING PARAMETERS

| Parameter | Frequency | Target/Threshold | Action if Abnormal | ED | HOSP | OPD | ICU |
|-----------|-----------|------------------|-------------------|:--:|:----:|:---:|:---:|
| Neurologic exam (cerebellar signs, gait, coordination) | Each visit; q8h if acute | Stable or improving | Worsening → repeat imaging; reassess diagnosis; adjust treatment | STAT | ROUTINE | ROUTINE | STAT |
| SARA score (Scale for Assessment and Rating of Ataxia) | Baseline, then q3-6 months | Stable or improving score | Progressive worsening → reassess etiology; intensify treatment/rehabilitation | - | ROUTINE | ROUTINE | - |
| Drug levels (phenytoin, lithium, carbamazepine) | At presentation if on these medications; then per drug monitoring schedule | Therapeutic range | Supratherapeutic → dose adjustment; discontinue if persistent cerebellar toxicity | STAT | ROUTINE | ROUTINE | STAT |
| MRI brain | Baseline; repeat at 6-12 months for progressive ataxia; earlier if worsening | Stable; no new lesions; atrophy pattern unchanged | New lesion → reassess diagnosis; progressive atrophy → adjust management | - | URGENT | ROUTINE | - |
| Blood glucose (on high-dose steroids) | q6h during IV steroids; QID during oral taper | 140-180 mg/dL inpatient | >200 → sliding scale insulin; endocrinology if persistent | - | ROUTINE | ROUTINE | ROUTINE |
| CBC (on immunosuppressive therapy) | q2 weeks x 3 months, then monthly (azathioprine/mycophenolate); q3 months (rituximab) | WBC >3000; ANC >1500; platelets >100,000 | Cytopenias → hold or reduce immunosuppression; infection evaluation | - | ROUTINE | ROUTINE | - |
| LFTs (on riluzole, immunosuppressants) | Monthly x 3 months, then q3 months (riluzole); monthly (azathioprine/mycophenolate) | ALT/AST <3x ULN | Elevated >3x → reduce dose; >5x → discontinue | - | ROUTINE | ROUTINE | - |
| Renal function (on immunotherapy, aminopyridine) | At baseline, then q3-6 months | Normal GFR | Declining → adjust renally-cleared medications (aminopyridine, gabapentin, pregabalin) | - | ROUTINE | ROUTINE | - |
| Immunoglobulin levels (on rituximab) | q6 months | IgG >500 mg/dL | Low IgG → supplement with IVIG; evaluate infection risk | - | ROUTINE | ROUTINE | - |
| Echocardiogram (Friedreich ataxia) | At diagnosis, then annually | No cardiomyopathy progression | LV hypertrophy or dysfunction → cardiology management; adjust exercise restrictions | - | ROUTINE | ROUTINE | - |
| HbA1c (Friedreich ataxia) | q6 months | <7.0% | Elevated → diabetes management; Friedreich ataxia has high rate of glucose intolerance/diabetes | - | ROUTINE | ROUTINE | - |
| Anti-gliadin antibodies (gluten ataxia) | q6 months after starting gluten-free diet | Decreasing titers | Persistent elevation → assess dietary compliance; dietitian reinforcement | - | - | ROUTINE | - |
| Fall risk assessment | Each visit | No falls | Recurrent falls → PT reassessment; home safety evaluation; assistive device upgrade | - | ROUTINE | ROUTINE | - |
| Swallowing function | At baseline if dysarthria present; repeat if worsening | Safe oral intake | Dysphagia → modified diet; speech therapy; PEG placement if severe (advanced disease) | - | ROUTINE | ROUTINE | - |

---

## 7. DISPOSITION CRITERIA

| Disposition | Criteria |
|-------------|----------|
| **Discharge home** | Clear etiology identified (drug toxicity with drug held, BPPV treated, B12 initiated); stable neurologic exam; safe ambulation (with or without assistive device); able to tolerate oral medications; outpatient follow-up arranged with neurology; no red flags for central cause |
| **Admit to floor** | New subacute ataxia requiring expedited workup (paraneoplastic panel, autoimmune labs, MRI with contrast); acute ataxia with diagnostic uncertainty; intractable nausea/vomiting requiring IV fluids and antiemetics; initiation of IV immunotherapy (steroids, IVIG); unsafe ambulation with high fall risk and inadequate home support |
| **Admit to ICU / Stroke unit** | Acute posterior fossa stroke (cerebellar infarction or hemorrhage); posterior fossa mass with mass effect or hydrocephalus; Wernicke encephalopathy with altered consciousness; basilar artery occlusion; need for emergent neurosurgical intervention (posterior fossa decompression, EVD) |
| **Transfer to higher level of care** | Posterior fossa stroke or mass requiring neurosurgical capability not available at current facility; need for endovascular intervention (basilar artery thrombectomy); need for specialized neurocritical care |
| **Outpatient follow-up** | Neurology follow-up in 2-4 weeks for chronic ataxia evaluation results; movement disorders follow-up in 4-8 weeks for genetic testing results; PCP within 1-2 weeks for medication adjustment; PT/OT within 1 week for ongoing rehabilitation |

---

## 8. EVIDENCE & REFERENCES

### Key Guidelines

| Guideline | Source | Year | Key Recommendation |
|-----------|--------|------|-------------------|
| Approach to the Patient with Chronic Progressive Ataxia | [Manto & Marmolino. Cerebellum 2009](https://pubmed.ncbi.nlm.nih.gov/19859773/) | 2009 | Systematic evaluation approach including history, exam, imaging, labs, and genetic testing |
| AAN Practice Parameter: Evaluation of Ataxia | [Fogel & Perlman. Neurology 2007](https://pubmed.ncbi.nlm.nih.gov/17303531/) | 2007 | Genetic testing algorithm based on clinical features; MRI as first-line imaging |
| European Guidelines for Spinocerebellar Ataxias | [van de Warrenburg et al. Eur J Neurol 2014](https://pubmed.ncbi.nlm.nih.gov/25540720/) | 2014 | Diagnostic approach and management of hereditary cerebellar ataxias |
| Treatment of Degenerative Ataxias | [Zesiewicz et al. Neurology 2018](https://pubmed.ncbi.nlm.nih.gov/29440566/) | 2018 | AAN guideline update on pharmacotherapy for degenerative ataxias; riluzole and aminopyridine evidence |

### Landmark Studies and Key Evidence

| Recommendation | Evidence Level | Source |
|----------------|----------------|--------|
| Paraneoplastic cerebellar degeneration — early tumor treatment improves outcomes | Class III, Level C | [Shams'ili et al. Brain 2003](https://pubmed.ncbi.nlm.nih.gov/12764061/) |
| Anti-GAD antibodies in autoimmune cerebellar ataxia — high titers (>2000 IU/mL) associated with cerebellar syndrome | Class III, Level C | [Honnorat et al. Brain 2001](https://pubmed.ncbi.nlm.nih.gov/11706981/) |
| Gluten ataxia — anti-gliadin antibodies in sporadic ataxia; response to gluten-free diet | Class III, Level C | [Hadjivassiliou et al. Lancet 1998](https://pubmed.ncbi.nlm.nih.gov/9843103/) |
| Gluten ataxia — most common cause of sporadic ataxia; anti-gliadin prevalence | Class III, Level C | [Hadjivassiliou et al. Brain 2003](https://pubmed.ncbi.nlm.nih.gov/12566288/) |
| 4-Aminopyridine effective for episodic ataxia type 2 and downbeat nystagmus | Class I, Level B | [Strupp et al. Neurology 2011](https://pubmed.ncbi.nlm.nih.gov/21734179/) |
| Riluzole for cerebellar ataxia — moderate improvement in SARA scores across mixed ataxia etiologies | Class I, Level B | [Romano et al. Lancet Neurol 2015](https://pubmed.ncbi.nlm.nih.gov/26321318/) |
| Acetazolamide for episodic ataxia type 2 — reduces episode frequency and severity | Class III, Level C | [Griggs et al. Ann Neurol 1978](https://pubmed.ncbi.nlm.nih.gov/677818/) |
| Omaveloxolone (Skyclarys) — FDA-approved for Friedreich ataxia; improved mFARS score | Class I, Level B | [Lynch et al. N Engl J Med 2024](https://pubmed.ncbi.nlm.nih.gov/41583108/) |
| IVIG for autoimmune cerebellar ataxia (anti-GAD) — case series showing improvement | Class IV, Level C | [Arino et al. JAMA Neurol 2014](https://pubmed.ncbi.nlm.nih.gov/24934144/) |
| Friedreich ataxia — natural history and cardiac involvement require surveillance | Class III, Level C | [Pandolfo. Arch Neurol 2008](https://pubmed.ncbi.nlm.nih.gov/18852343/) |
| SARA scale — validated rating scale for cerebellar ataxia assessment and monitoring | Validation study | [Schmitz-Hubsch et al. Neurology 2006](https://pubmed.ncbi.nlm.nih.gov/16769946/) |
| Alcohol-related cerebellar degeneration — anterior vermis atrophy pattern; abstinence may halt progression | Class III, Level C | [Fitzpatrick et al. Eur Radiol 2008](https://pubmed.ncbi.nlm.nih.gov/18034347/) |
| MSA-C diagnostic criteria and natural history | Consensus criteria | [Gilman et al. Neurology 2008](https://pubmed.ncbi.nlm.nih.gov/18725592/) |
| Thiamine replacement for Wernicke encephalopathy — IV thiamine prevents permanent cerebellar damage | Class III, Level C | [Galvin et al. J Neurol Neurosurg Psychiatry 2010](https://pubmed.ncbi.nlm.nih.gov/21294435/) |
| Rituximab for autoimmune cerebellar ataxia — emerging evidence for anti-GAD and paraneoplastic | Class IV, Level C | [Jarius et al. J Neuroimmunol 2010](https://pubmed.ncbi.nlm.nih.gov/20813415/) |

---

## CHANGE LOG

**v1.1 (January 31, 2026)**
- Fixed structured dosing format across all treatment tables (3A, 3B, 3C, 3D) to standard [dose] :: [route] :: [frequency] :: [instructions]
- Expanded cross-references to self-contained content: Tenecteplase contraindications/monitoring (was "Same as alteplase"); MRA/MR spectroscopy contraindications (was "Same as MRI")
- Added ICU column to Sections 4A, 4B, 4C (Referrals, Patient Instructions, Lifestyle)
- Added ICU column to Section 6 (Monitoring Parameters)
- Added ICU coverage (STAT) for acute treatments in 3A: thiamine, alteplase, tenecteplase, dexamethasone, mannitol, hypertonic saline, phenytoin adjustment, lithium adjustment
- Added ICU coverage (STAT) for core labs (1A): CBC, CMP, glucose, magnesium, drug levels, blood alcohol, urinalysis, thiamine, ESR/CRP, B12
- Added ICU coverage for essential imaging (2A): CT head (STAT), MRI brain (URGENT), MRA/CTA (URGENT)
- Added ICU coverage for acute-relevant referrals (4A): neurology (URGENT), stroke neurology (STAT), neurosurgery (STAT)
- Added ICU coverage for acute monitoring (Section 6): neurologic exam (STAT), drug levels (STAT), blood glucose on steroids (ROUTINE)
- Updated frontmatter settings from "ED, HOSP, OPD" to "ED, HOSP, OPD, ICU"
- Changed Gluten-free diet route from "PO" to "Dietary" for accuracy
- Fixed directive language: "consider ICP management" → "initiate ICP management"; "consider IVIG supplementation" → "supplement with IVIG"; "consider PEG" → "PEG placement"
- Fixed Lithium row: moved "Monitor for rebound mania" from Contraindications to properly note as "Psychiatry consult before discontinuation; monitor for rebound mania"
- Standardized Phenytoin/Lithium adjustment dosing fields to use N/A for dose when action is dose-hold rather than administration
- Fixed Buspirone starting dose field from "10 mg" to "5 mg" to match full instructions

**v1.0 (January 30, 2026)**
- Initial template creation
- Comprehensive 8-section format covering acute, subacute, and chronic ataxia
- Full differential diagnosis tables (cerebellar vs. sensory; tempo-based; MRI atrophy patterns)
- Complete treatment tables with structured dosing format
- Evidence section with PubMed citation links
- Settings: ED, HOSP, OPD (ICU marked "-" for most items)

---

## APPENDIX A: Systematic Approach to Ataxia Evaluation

### Step 1: Localize the Ataxia
- **Cerebellar ataxia:** Dysmetria, intention tremor, dysdiadochokinesia, nystagmus, scanning speech, wide-based gait (NOT worse with eye closure)
- **Sensory ataxia:** Positive Romberg, loss of proprioception/vibration, pseudoathetosis, stamping gait (WORSE with eye closure)
- **Mixed:** Some conditions (Friedreich ataxia, MSA-C) involve both

### Step 2: Determine Tempo
- **Acute (hours-days):** Stroke, toxic, Wernicke, post-infectious
- **Subacute (weeks-months):** Paraneoplastic, autoimmune, nutritional, CJD
- **Chronic (months-years):** Hereditary, degenerative, alcoholic
- **Episodic (discrete attacks):** Channelopathies (EA1, EA2), vestibular migraine, TIA

### Step 3: Identify Key Clinical Features
- Family history → hereditary (SCA, Friedreich, EA)
- Cancer history or smoking → paraneoplastic
- Alcohol use → alcoholic cerebellar degeneration
- Medication use (phenytoin, lithium, carbamazepine) → drug toxicity
- GI symptoms or weight loss → gluten ataxia, malabsorption
- Autonomic failure → MSA-C
- Cardiomyopathy + scoliosis + young onset → Friedreich ataxia
- Telangiectasias + immunodeficiency → ataxia-telangiectasia
- Ophthalmoplegia + confusion → Wernicke encephalopathy

### Step 4: Order Investigations by Priority
1. **STAT (ED):** CT head (hemorrhage), drug levels, blood glucose, thiamine, blood alcohol
2. **Urgent:** MRI brain with DWI and contrast, essential labs (B12, CMP, TSH, ESR/CRP)
3. **Routine:** Anti-GAD, anti-gliadin, paraneoplastic panel, NCS/EMG, spine MRI
4. **Extended:** Genetic testing (SCA panel, Friedreich), whole exome, rare antibodies, metabolic studies

## APPENDIX B: Hereditary Ataxia Quick Reference

| Condition | Gene/Mutation | Inheritance | Age of Onset | Key Features |
|-----------|--------------|-------------|-------------|--------------|
| **Friedreich ataxia** | FXN (GAA expansion) | Autosomal recessive | 5-25 years (classic) | Cardiomyopathy, scoliosis, diabetes, sensory neuropathy, absent DTRs, upgoing toes |
| **SCA1** | ATXN1 (CAG expansion) | Autosomal dominant | 30-40 years | Cerebellar ataxia, ophthalmoparesis, pyramidal signs, peripheral neuropathy |
| **SCA2** | ATXN2 (CAG expansion) | Autosomal dominant | 30-40 years | Slow saccades (hallmark), cerebellar ataxia, peripheral neuropathy, hyporeflexia |
| **SCA3 (Machado-Joseph)** | ATXN3 (CAG expansion) | Autosomal dominant | 30-50 years | Most common SCA; cerebellar ataxia, ophthalmoplegia, pyramidal and extrapyramidal signs, faciolingual myokymia |
| **SCA6** | CACNA1A (CAG expansion) | Autosomal dominant | >50 years | Pure cerebellar; slowly progressive; downbeat nystagmus; episodic features early |
| **SCA7** | ATXN7 (CAG expansion) | Autosomal dominant | 20-40 years | Retinal degeneration (visual loss, macular dystrophy) + cerebellar ataxia |
| **Episodic ataxia type 1** | KCNA1 | Autosomal dominant | Childhood | Brief attacks (minutes); myokymia between attacks; responds to carbamazepine |
| **Episodic ataxia type 2** | CACNA1A | Autosomal dominant | Childhood-young adult | Attacks last hours; interictal nystagmus; responds to acetazolamide |
| **Ataxia-telangiectasia** | ATM | Autosomal recessive | 1-4 years | Telangiectasias (conjunctival, ear, skin); immunodeficiency; elevated AFP; cancer predisposition |
| **MSA-C** | Not genetic (sporadic) | N/A | 50-60 years | Rapidly progressive cerebellar ataxia + autonomic failure (orthostatic hypotension, urinary dysfunction); hot cross bun sign on MRI |

---

*This template represents the initial build phase and requires validation through the checker pipeline before clinical deployment.*
